Onconova Therapeutics Story Overview

ONTX -- USA Stock  

USD 3.44  0.24  6.52%

Macroaxis does not monitor all media channels or aggregates social signals for Onconova Therapeutics. But even though we do not provide professional-grade financial sentiment analysis on Onconova Therapeutics, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Onconova Therapeutics. Additionally take a look at Onconova Therapeutics Hype Analysis, Onconova Therapeutics Correlation and Onconova Therapeutics Performance.
Conversion by Michael Hoffman of 140449 shares of Onconova Therapeutics
Filed transaction by Onconova Therapeutics Inc director. Derivative codes conversion of derivative security

Onconova Therapeutics Inc insider trading alert for conversion of series c convertible preferred stock by Michael Hoffman, the corporate stakeholder, on March 8, 2018. This event was filed by Onconova Therapeutics Inc with SEC on 2013-08-01. Statement of changes in beneficial ownership - SEC Form 4

Story Momentum

This media report from MacroaxisInsider distributed on March 8, 2018 was a factor to the next trading day price appreciation.The trading delta at closing time against the next closing price was 0.94% . The trading delta at closing time when the story was published against the current closing price is 247.17% .

Similar stores for Onconova Therapeutics

Investment Analysts Weekly Ratings Updates for Onconova Therapeutics - Fairfield Currentnews
Investment Analysts Weekly Ratings Updates for Onconova Therapeutics Fairfield CurrentSeveral brokerages have updated their recommendations and price targets on shares of Onconova Therapeutics in the last few weeks ...
Onconova Therapeutics Reports Phase 2 Trial of Oral Rigosertib in Combination with Azacitidine in Myelodysplas...Street Insider News
Onconova Therapeutics Reports Phase 2 Trial of Oral Rigosertib in Combination with Azacitidine in Myelodysplastic Syndromes StreetInsider.comGet instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. Onconova Therapeutics, Inc. ...
over a week ago at http://seekingalpha.com 
Onconova Therapeutics The Many Strengths Of INSPIRE - Seeking Alpha
seekingalpha News
Onconova Therapeutics The Many Strengths Of INSPIRE Seeking AlphaOnconovas INSPIRE confirmatory trial is a fascinating construct. Its cutting-edge Adaptive features make it resilient to failure. Valuation of Onconova assumin.
over two weeks ago at http://pressoracle.com 
Renaissance Technologies LLC Buys 672312 Shares of Onconova Therapeutics Inc
news
PressOracleFull coverage
over three weeks ago at http://www.baseballdailydigest.com 
Onconova Therapeutics Releases Earnings Results, Misses Estimates By 0.16 EPS
news
Baseball Daily NewsFull coverage
over a month ago at http://nysedaily.com 
Is this stock is Attractive Onconova Therapeutics
news
NYSE DAILY Full coverage
over a month ago at http://whatsonthorold.com 
Time to Sell Onconova Therapeutics, Inc. After The Completion of This Double Bottom Chart Pattern
news
Thorold NewsFull coverage
over a month ago at http://xnewspress.com 
Onconova Therapeutics Stock Rating Reaffirmed by HC Wainwright
news
XNewsPressFull coverage
over a month ago at http://www.streetinsider.com 
Onconova Therapeutics Secures New Patent from USPTO for Rigosertib
Street Insider News
StreetInsider.comOnconova Therapeutics, Inc. EPS Estimated At -0.05 Thorold NewsFull coverage
over a month ago at http://pressoracle.com 
Onconova Therapeutics Given Buy Rating at HC Wainwright
news
PressOracleFull coverage
over two months ago at http://www.fairfieldcurrent.com 
Onconova Therapeutics Rating Reiterated by HC Wainwright
news
Fairfield CurrentFull coverage
over three months ago at http://thewellesleysnews.com 
Analyst Stock Ratings DelMar Pharmaceuticals, Inc. , Onconova Therapeutics, Inc.
news
Analyst JournalFull coverage
over six months ago at http://alphabetastock.com 
Hot Stocks Highlights Onconova Therapeutics Inc
news
Alpha Beta StockFull coverage

Price to Sales

Price to Sales Comparative Analysis

Onconova Therapeutics is currently under evaluation in price to sales category among related companies. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Additionally take a look at Onconova Therapeutics Hype Analysis, Onconova Therapeutics Correlation and Onconova Therapeutics Performance. Please also try Equity Valuation module to check real value of public entities based on technical and fundamental data.
Search macroaxis.com